US/UK/Canada

Share

Contacts

  • AstraZeneca
    Karlebyhus, Astraallén 151 85 SÖDERTÄLJE
    08-553 260 00
    08-553 290 00
    http://www.astrazeneca.se
    • Pick a time period -
    Tags ( Active)

    AstraZeneca licenses novel EGFR inhibitor

    14 July 2026 AstraZeneca enters exclusive global license agreement for novel oralEGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical Complements AstraZeneca’s leading portfolio of medicines targeting EGFR mutations Zegfrovy is approved in the US and China to treat lung cancer patients whose tumours carry exon 20 insertion mutations AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer.

    Update on CARDIO-TTRansform Phase III trial

    [This announcement contains inside information]   9 July 2026   Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy   The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to 140 weeks compared with placebo. Wainua was generally well tolerated, with a safety

    Admission of Further Securities to Trading

    1 July 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R. +--+--------------------------+----------------------------------------------+|1 |Details of the issuer |+--+--------------------------+----------------------------------------------+|a)|Name |AstraZeneca PLC |+--+--------------------------+------------------

    Total Voting Rights

    1 July 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 June 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,024,534 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,024,534. The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify

    Enhertu approved in EU for HER2+ solid tumours

    29 June 2026 Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which demonstrated clinically meaningful responses across a broad range of tumours AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC]

    Datroway recommended for approval in EU for TNBC

    29 June 2026   Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy Recommendation based on TROPION-Breast02 Phase III trial where AstraZeneca and Daiichi Sankyo's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival   If approved, Datroway has the potential to be the first TROP2-directed antibody drug conjugate for patients in the EU with a

    Truqap approved in US for prostate cancer

    15 June 2026 Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed Truqap combination reduced risk of radiographic disease progression or death by 19% First-in-class AKT inhibitor moves into second tumour type to address an aggressive form of prostate cancer associated with poor prognosis AstraZeneca's Truqap (capivasertib) in combination with abiraterone and prednisone has been approved in the US as

    Admission of Further Securities to Trading

    1 June 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R. 1 Details of the issuera) Name AstraZeneca PLCb) LEI PY6ZZQWO2IZFZC3IOL082 Details of the transferable securities admitted to tradinga) Name, type and Ordinary Shares of $0.25 identification code eachISIN: GB0009895292b) Regulated market London Stock

    Total Voting Rights

    1 June 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 May 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,009,750 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,009,750. The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify

    Imfinzi approved in US for early bladder cancer

    29 May 2026   Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer   Based on POTOMAC Phase III trial results which showed a 32% reduction in the risk of high-risk disease recurrence, progression or death after one year of Imfinzi added to BCG vs. BCG alone                                             AstraZeneca's Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients

    US FDA decision date on camizestrant extended

    27 May 2026 US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data The US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date to review additional data requested to support the New Drug Application (NDA) for camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumours have an

    Datroway approved in US for 1L triple-negative BC

    26 May 2026   Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates AstraZeneca and Daiichi Sankyo's Datroway is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival of approximately two years based on the TROPION-Breast02 Phase III trial   Datroway has the potential to become the new standard of care in this setting

    Enhertu recommended in EU for HER2+ solid tumours

    26 May 2026 Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showed clinically meaningful responses across a broad range of tumours If approved, Enhertu would become the first HER2-directed therapy and antibody drug conjugate to receive a tumour agnostic indication in the EU   AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a

    Camizestrant recommended for breast cancer in EU

    26 May 2026   Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer Recommendation based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumour mutation If approved, camizestrant has the potential to reshape 1st-line treatment for patients in Europe with this type of advanced breast cancer AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (

    Director/PDMR Shareholding

    18 May 2026     Transaction by Person Discharging Managerial Responsibilities     AstraZeneca PLC (the Company) announced that, on 14 May 2026, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to Pascal Soriot, Executive Director and Chief Executive Officer, under the terms of the AstraZeneca Performance Share Plan (AZPSP).   The AZPSP award was granted on 14 May 2021 as part of the award granted to Mr Soriot on 5 March 2021, and reflected the revised limits of the AZPSP, as approved by shareholders at the Company's 2021 Annual General

    Enhertu approved in two HER2+ early BC settings

    18 May 2026 Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial Two new indications bring AstraZeneca and Daiichi Sankyo's Enhertu into curative-intent setting, reinforcing its role across stages of HER2-positive breast cancer AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant

    Baxfendy approved in the US for hypertension

    18 May 2026 Baxfendyapproved in the US as the first and only aldosterone synthase inhibitortreatment for adults with hypertension Approval based on BaxHTN Phase III results showing statistically significant and clinically meaningful reduction in systolic blood pressure in patients with uncontrolled or resistant hypertension Baxfendy 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline in BaxHTN trial AstraZeneca's Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of

    Imfinzi + EV improves EFS & OS in bladder cancer

    14 May 2026 Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial Perioperative Imfinzi plus Imjudo and neoadjuvant EV showed a statistically significant and clinically meaningful improvement in event-free survival and a favourable trend for overall survival High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with Imfinzi (durvalumab) in combination with

    Total Voting Rights and Admission of Shares

    1 May 2026 Total Voting Rights and Notification of Admission of Further Securities to Trading (PRM 1.6.4R) Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 April 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,550,995,630 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,995,630. The above figure for the total number of voting rights may be used by shareholders as

    FDA ODAC vote on camizestrant in breast cancer

    01 May 2026 Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation,

    FDA ODAC recommends Truqap in prostate cancer

    01 May 2026 Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer ODAC overwhelming majority voted that Truqap plus abiraterone and ADT demonstrated a favourable benefit risk profile for patients based on the CAPItello-281 Phase III trial results First and only targeted treatment combination to demonstrate benefit in this subtype of prostate cancer addresses significant unmet patient need The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for

    Breztri approved in the US for asthma

    28 April 2026   Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older   Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca's single-inhaler fixed-dose triple therapy compared with inhaled dual therapy   Approval is second indication for Breztri beyond COPD      AstraZeneca's fixed-dose triple-combination therapy Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate or BGF 320/36/9.6μg) has been approved in the

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe